Denmark's Genmab Q1 operating profit misses estimates

Genmab A/S

07/05/2026 16:11

Overview

Denmark biotech's Q1 revenue grew 25% yr/yr, driven by higher royalties and product sales

Q1 operating profit missed analyst expectations

Company maintained 2026 financial guidance and highlighted late-stage portfolio investment

Outlook

Genmab is maintaining its 2026 financial guidance published February 17, 2026

Company continues launch readiness for Rina-S and petosemtamab

Result Drivers

ROYALTY REVENUE - Higher royalties from DARZALEX and Kesimpta collaborations drove revenue growth

PRODUCT SALES - Higher EPKINLY net product sales contributed to revenue increase

PIPELINE INVESTMENT - Increased operating expenses due to pipeline expansion and commercialization efforts for Rina-S and petosemtamab

Company press release: ID:nGNE6Hgwh6

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Operating Profit
Miss
$180 mln
$184.68 mln (7 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy", 3 "hold" and 2 "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Genmab A/S is DKK2,300.00, about 30% above its May 6 closing price of DKK1,769.50

The stock recently traded at 20 times the next 12-month earnings vs. a P/E of 21 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)